Fetuin-A is related to syndesmophytes in patients with ankylosing spondylitis: A case control study

Clinics

Volumn 69, Issue 10, 2014, Pages 688-693

  Tuylu, Tugba ^a   Sari, Ismail ^a   Solmaz, Dilek ^a   Kozaci, Didem Leyla ^b,b   Gunay, Necati ^b   Onen, Fatos ^a   Akkoc, Nurullah ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

Ankylosing Spondylitis; Bone Formation; Bone Morphogenetic Protein 7; Dickkopf 1 Protein Human; Fetuin A; Sclerostin Protein Human

Indexed keywords

BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; C REACTIVE PROTEIN; DKK1 PROTEIN, HUMAN; FETUIN A; GENETIC MARKER; INTERLEUKIN 6; OSTEOGENIC PROTEIN 1; SIGNAL PEPTIDE; SOST PROTEIN, HUMAN;

ADULT; ANALYSIS OF VARIANCE; ANKYLOSING SPONDYLITIS; BLOOD; CASE CONTROL STUDY; CERVICAL SPINE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC MARKER; HETEROTOPIC OSSIFICATION; HUMAN; LUMBAR VERTEBRA; MALE; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; RADIOGRAPHY; REFERENCE VALUE;

ADULT; ALPHA-2-HS-GLYCOPROTEIN; ANALYSIS OF VARIANCE; BIOMARKERS; BONE MORPHOGENETIC PROTEIN 7; BONE MORPHOGENETIC PROTEINS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CERVICAL VERTEBRAE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSSIFICATION, HETEROTOPIC; REFERENCE VALUES; SPONDYLITIS, ANKYLOSING; STATISTICS, NONPARAMETRIC;

EID: 84920490140     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2014(10)07     Document Type: Article

References (36)

1. Poddubnyy D, Sieper J. Radiographic progression in ankylosing spondylitis/axial spondyloarthritis: how fast and how clinically meaningful? Curr Opin Rheumatol. 2012;24(4):363-9, http://dx.doi.org/10.1097/BOR.0b013e328352b7bd
2. Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis. 2007;66(7):910-5, http://dx.doi.org/10.1136/ard.2006.066415
3. Schett G, Rudwaleit M. Can we stop progression of ankylosing spondylitis? Best Pract Res Clin Rheumatol. 2010;24(3):363-71, http://dx.doi.org/10.1016/j.berh.2010.01.005
4. Sari I, Kebapcilar L, Taylan A, Bilgir O, Kozaci DL, Yildiz Y, et al. FetuinA and interleukin-18 levels in ankylosing spondylitis. Int J Rheum Dis. 2010;13(1):75-81
5. Mori K, Emoto M, Inaba M. Fetuin-A: a multifunctional protein. Recent Pat Endocr Metab Immune Drug Discov. 2011;5(2):124-46, http://dx.doi.org/10.2174/187221411799015372.
6. Heiland GR, Zwerina K, Baum W, Kireva T, Distler JH, Grisanti M, et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis. 2010;69(12):2152-9, http://dx.doi.org/10.1136/ard.2010.132852
7. Park MC, Park YB, Lee SK. Relationship of bone morphogenetic proteins to disease activity and radiographic damage in patients with ankylosing spondylitis. Scand J Rheumatol. 2008;37(3):200-4
8. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and rheumatism. 1984;27(4):361-8, http://dx.doi.org/10.1002/art.1780270401
9. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-91
10. Calin A, Garrett S, Whitelock H, Kennedy LG, O9Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21(12):2281-5
11. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994;21(9):1694-8
12. Sato H, Kazama JJ, Wada Y, Kuroda T, Narita I, Gejyo F, et al. Decreased levels of circulating alpha2-Heremans-Schmid glycoprotein/Fetuin-A (AHSG) in patients with rheumatoid arthritis. Intern Med. 2007;46 (20):1685-91, http://dx.doi.org/10.2169/internalmedicine.46.6269
13. Laughlin GA, Cummins KM, Wassel CL, Daniels LB, IxJH.The association of fetuin-A with cardiovascular disease mortality in older communitydwelling adults: the Rancho Bernardo study. J Am Coll Cardiol. 2012;59(19):1688-96, http://dx.doi.org/10.1016/j.jacc.2012.01.038
14. van Oss CJ, Bronson PM, Border JR. Changes in the serum alpha glycoprotein distribution in trauma patients. J Trauma. 1975;15(5):451-5
15. Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Ostergaard M, Lambert RG. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis and rheumatism. 2009;60(1):93-102, http://dx.doi.org/10.1002/art.24132
16. Kazama JJ, Gejyo F, Ei I. The immunohistochemical localization of alpha2-Heremans-Schmid glycoprotein/fetuin-A (AHSG). Nephrol Dial Transplant. 2005;20(4):851-2, http://dx.doi.org/10.1093/ndt/gfh690
17. Jahnen-Dechent W, Heiss A, Schafer C, Ketteler M. Fetuin-A regulation of calcified matrix metabolism. Circ Res. 2011;108(12):1494-509, http://dx.doi.org/10.1161/CIRCRESAHA.110.234260
18. Brown WM, Saunders NR, Mollgard K, Dziegielewska KM. Fetuin–an old friend revisited. Bioessays. 1992;14(11):749-55, http://dx.doi.org/10.1002/bies.950141105
19. Toroian D, Price PA. The essential role of fetuin in the serum-induced calcification of collagen. Calcif Tissue Int. 2008;82(2):116-26, http://dx.doi.org/10.1007/s00223-007-9085-2
20. Ix JH, Wassel CL, Bauer DC, Toroian D, Tylavsky FA, Cauley JA, et al. Fetuin-A and BMD in older persons: the Health Aging and Body Composition (Health ABC) study. J Bone Miner Res. 2009;24(3):514-21, http://dx.doi.org/10.1359/jbmr.081017
21. Price PA, Toroian D, Lim JE. Mineralization by inhibitor exclusion: the calcification of collagen with fetuin. J Biol Chem. [In Vitro];284(25): 17092-101
22. Schett G. Bone formation versus bone resorption in ankylosing spondylitis. Adv Exp Med Biol. 2009;649:114-21, http://dx.doi.org/10.1007/978-1-4419-0298-6_8
23. Daoussis D, Andonopoulos AP. The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling? Semin Arthritis Rheum. 2011;41(2):170-7, http://dx.doi.org/10.1016/j.semarthrit.2011.01.006
24. Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71(4):572-4, http://dx.doi.org/10.1136/annrheumdis2011-200216
25. Korkosz M, Gasowski J, Leszczynski P, Pawlak-Bus K, Jeka S, Kucharska E, et al. High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage. BMC Musculoskelet Disord. 2013;14:99, http://dx.doi.org/10.1186/14712474-14-99
26. Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis and rheumatism. 2010;62(1):150-8, http://dx.doi.org/10.1002/art.27231
27. Hu Z, Xu M, Li Q, Lin Z, Liao Z, Cao S, et al. Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis. Int J Rheum Dis. 2012;15(4):358-65.
28. Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY, et al. Dickkopf-1 levelislowerinpatientswithankylosingspondylitisthaninhealthypeople and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int. 2012;32(8):2523-7, http://dx.doi.org/10.1007/s00296-011-1981-0
29. Taylan A, Sari I, Akinci B, Bilge S, Kozaci D, Akar S, et al. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord. 2012;13:191, http://dx.doi.org/10.1186/1471-2474-13-191
30. Beyer C, Schett G. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Novel targets in bone and cartilage. Best Pract Res Clin Rheumatol. 2010;24(4):489-96, http://dx.doi.org/10.1016/j.berh.2010.03.001
31. Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis and rheumatism. 2009;60(11):3257-62, http://dx.doi.org/10.1002/art.24888
32. Saad CG, Ribeiro AC, Moraes JC, Takayama L, Goncalves CR, Rodrigues MB, et al. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther. 2012;14(5):R216, http://dx.doi.org/10.1186/ar4055
33. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest. 2005;115(6):1571-9, http://dx.doi.org/10.1172/JCI23738
34. Chen HA, Chen CH, Lin YJ, Chen PC, Chen WS, Lu CL, et al. Association of bone morphogenetic proteins with spinal fusion in ankylosing spondylitis. The Journal of rheumatology. 2010;37(10):2126-32, http://dx.doi.org/10.3899/jrheum.100200
35. Wendling D, Cedoz JP, Racadot E. Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy. Joint Bone Spine. 2008;75(5):559-62, http://dx.doi.org/10.1016/j.jbspin.2008.01.026
36. Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine. 2007;74(3):304-5, http://dx.doi.org/10.1016/j.jbspin.2006.11.005.